Healios AG Named as a Finalist For The Coveted 2022 Swiss Medtech Award

Healios AG, a MedTech company focused on developing and validating digital biomarkers since 2014, has been named one of three finalists for the 2022 Swiss Medtech Award. Healios AG has made it into the finals thanks to their smartphone technology that monitors the neurological functions of multiple sclerosis (MS) patients. Healios AG collaborated with the Research Centre for Clinical Neuroimmunology and Neuroscience (RC2NB, division of University Hospital Basel) to develop DreaMSᴹᴰ, CE Mark (Class I), a smartphone technology for patients with MS. DreaMSᴹᴰ is an app- based program that assesses patients’ neurological function as they perform their daily activities. It focuses on areas that typically cause MS patients difficulty, such as movement, dexterity, cognition, and vision. The smartphone app collects data from the individual’s smartphone, which is then analyzed by algorithms to calculate digital metrics. DreaMSᴹᴰ is a Software Medical Device, cleared by the European Medicine Agency (EMA).

“Being named as a finalist for such a competitive and prestigious award is truly an honor. Thank you Swiss MedTech for recognizing Healios AG. The DreaMSᴹᴰ app is poised to not only attribute to significant, progressive strides forward in the care and treatment of MS patients, but also further amplify innovation by Swiss MedTech companies to impact research and clinical management worldwide. Additionally, we are proud to share in celebrating this achievement with fellow finalists, AlveoliX AG and Biospectal SA, and their innovative technology“ said Guilhem Dupont, Healios AG Founder and Chief Executive Officer.